* Y-mAbs Therapeutics Inc YMAB.OQ reported a quarterly
adjusted
loss of 16 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -18 cents. The mean expectation of
eight analysts for the quarter was for a loss of 16 cents per
share. Wall Street expected results to range from -24 cents
to -9 cents per share.
* Revenue fell 9.7% to $18.46 million from a year ago;
analysts
expected $23.26 million.
* Y-mAbs Therapeutics Inc's reported EPS for the quarter was
a
loss of 16 cents.
* The company reported a quarterly loss of $7 million.
* Y-mAbs Therapeutics Inc shares had risen by 18.3% this
quarter and gained 128.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 11.2%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is 21.50
This summary was machine generated from LSEG data November 8 at
04:24 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.16 -0.16 Met
Jun. 30 2024 -0.13 -0.21 Missed
Mar. 31 2024 -0.14 -0.15 Missed
Dec. 31 2023 -0.20 -0.02 Beat